|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Industry in the United States
Aruvian's R'search, Oct 2009, Pages: 150
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease.
Between 1995 and 2005, more than 300 new drugs, biologics, and vaccines that prevent and treat over 150 conditions were approved by the FDA.3 The FDA also gave the go-ahead for numerous new indications for previously approved medicines, allowing physicians to tailor treatment strategies to meet a patient’s individual disease status, past medication history, side effect tolerance, and preferences.
The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The industry has undergone dramatic structural changes over the past few decades, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.
The pharmaceutical industry is under mounting scrutiny because of rapidly increasing expenditures for drugs in the United States. Drug expenditures are now the fastest-growing component of health care costs, increasing at the rate of about 15 percent per year. They account for about eight percent of health care spending, and at their current rate of increase, they will soon surpass spending for physicians services and, for many health maintenance organizations (HMOs), the costs of hospitalization.
Aruvian Research brings you a complete analysis of the Pharmaceutical Industry in the United States. The report covers a brief profile of the global pharmaceutical industry, the TRIPS agreement and the effect of the agreement on the US pharmaceutical industry, offshoring in the pharmaceutical industry, economic trends in the industry, competition in the industry, and key trends in the pharmaceutical supply chain in the United States.
The report also analyzes the US pharmaceutical industry through two frameworks - a PEST analysis and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, impact of the Hatch-Waxman Act, and the role of the government in the industry.
Complete with a comprehensive section on the research and development going on in the US pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about the US Pharmaceutical Industry.
Customers who bought this item also bought
Looking at Offshoring in the Pharmaceutical Industry
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
The Pharmaceutical Market: USA
Analyzing the Global Pharmaceutical Industry
Pharmaceutical Industry in South Korea
Pharmaceutical Industry in Taiwan
Pharmaceutical Industry in Denmark
Pharmaceutical Industry in Japan
Pharmaceutical Industry in Brazil
Pharmaceutical Industry in Mexico
Pharmaceutical Industry in Poland
Pharmaceutical Industry in Sweden
|
|
|
|
